Gilgamesh is a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders.

Gilgamesh's mission is to develop novel compounds that capture the therapeutic benefits of psychedelics to fundamentally reshape the treatment of mental illness.

Gilgamesh was founded in 2019 by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin and, Mike Cunningham. The company is headquartered in New York.

Gilgamesh's AI-powered behavioral and imaging driven platform is accelerating and optimizing the development of our new chemical entities (NCEs) which offer improved safety, tolerability, duration, and efficacy.

Gilgamesh's product pipelines include 2 lead programs, GM-1020 and GM-2505 through Phase 1/1b safety and efficacy studies. Gilgamesh is also advancing multiple discovery programs that will fuel its pipeline over the coming years.

Gilgamesh's cutting edge approach incorporates machine learning algorithms to systematically characterize the multidimensional bioactivity of known and novel psychoactive molecules to improve clinical translation.

Gilgamesh is backed by Prime Movers Lab, Alumni Ventures, Y Combinator, JLS Fund, Satori Capital, Palo Santo, Negev Capital, Route 66, Gron Ventures, and others. The company raised $39M in a Series B round on Dec 15, 2022. This brings Gilgamesh's total funding to $68.6M to date.